FDA Seeks Comments on Human Tissue Paperwork Collection Renewal
Published Date: 9/9/2026
Notice
Summary
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with statutory and regulatory requirements that govern certain human cells, tissues, and cellular and tissue-based products (HCT/Ps).
Analyzed Economic Effects
5 provisions identified: 0 benefits, 5 costs, 0 mixed.
Mandatory HCT/P Registration and Listing
If your establishment recovers, processes, stores, labels, packages, or distributes human cells, tissues, or cellular and tissue-based products (HCT/Ps) regulated solely under section 361 of the Public Health Service Act, you must register and submit a list of each HCT/P using Form FDA 3356. FDA estimates 2,531 total annual respondents (2,374 existing registrants and 157 new registrants) and requires registration whether or not the HCT/P enters interstate commerce.
Extensive Recordkeeping and SOP Obligations
Establishments must establish and maintain standard operating procedures (SOPs) and records documenting methods, facilities, and controls used for manufacture of HCT/Ps, including recovery, donor screening/testing, processing, storage, labeling, packaging, and distribution. FDA estimates recordkeeping burden includes 157 recordkeepers establishing SOPs at 48 hours each (7,536 hours), 2,374 recordkeepers updating SOPs at 24 hours each (56,976 hours), and a total recordkeeping burden of 2,235,005 hours annually for part 1271.
Large Third-Party Disclosure Burden
Certain provisions require disclosure of information to third parties as part of good tissue practice/CGTP; FDA estimates 1,611 respondents will make a combined total of 8,030,435 disclosures annually, with an estimated 2,389,226 hours of burden each year for those disclosures. These disclosures relate to distribution and other CGTP requirements.
Specific Reporting Duties and Hours
Part 1271 requires establishments to submit specific reports such as initial registrations (2,374 responses), new establishment registrations (157 responses), updates to listings (566 responses), location/ownership amendments (346 responses), adverse action reports (214 responses), import notifications (560 responses), and other filings. FDA estimates the total annual reporting burden across these activities is 2,102 hours.
Required Electronic Submission via eHCTERs
FDA requires electronic submission of establishment registration and product listing information through the Electronic Human Cell and Tissue Establishment Registration System (eHCTERs) using Form FDA 3356 under Sec. 1271.22. A request for waiver of the electronic format may be submitted under Sec. 1271.23, and if granted, establishments may submit a paper Form FDA 3356 by mail.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18368, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates." This guidance describes the FDA's regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities. This guidance is being published for immediate implementation due to the expected market exit of the predominant source of certain starter parenteral nutrition drug products for neonates in the United States.
2026-18299, Agency Information Collection Activities; Proposed Collection; Comment Request; Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers To Advance Pregnancy Safety Data Collection and Improve Health Communications
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled "Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers to Advance Pregnancy Safety Data Collection and Improve Health Communications."
2026-18023, Determination That PHENAPHEN WITH CODEINE NO. 3 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 30 Milligrams, and PHENAPHEN WITH CODEINE NO. 4 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that PHENAPHEN WITH CODEINE NO. 3 (acetaminophen; codeine phosphate) oral capsules, 325 milligrams (mg) and 30 mg, and PHENAPHEN WITH CODEINE NO. 4 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 60 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for PHENAPHEN WITH CODEINE NO. 3 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 30 mg, and PHENAPHEN WITH CODEINE NO. 4 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 60 mg, if all other legal and regulatory requirements are met.
Previous / Next Documents
Previous: 2026-18332, Notice of Inventory Completion: Birmingham Museum of Art, Birmingham, AL
In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the Birmingham Museum of Art (BMA) has completed an inventory of human remains and has determined that there is a cultural affiliation between the human remains and Indian Tribes or Native Hawaiian organizations in this notice.
Next: 2026-18335, Notice of Intended Repatriation: Milwaukee Public Museum, Milwaukee, WI
In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the Milwaukee Public Museum intends to repatriate certain cultural items that meet the definition of sacred objects and that have a cultural affiliation with the Indian Tribes or Native Hawaiian organizations in this notice.